STAT+: Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says
STAT
DECEMBER 10, 2024
Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major drugmaker to do so, CEO David Ricks said Tuesday. Emerging research suggests that GLP-1 drugs — Zepbound is one such treatment — not only reduce food cravings but may also suppress desires for other substances.
Let's personalize your content